Eli Lilly & Co. (LLY) Pre-Earnings Moves: Buy or Watch?
Eli Lilly (LLY) saw steady growth in its last reported quarter, driven by sales from its popular diabetes drug Mounjaro. The stock has had an impressive run over the past year. However, will the momentum be sustained following its upcoming earnings release scheduled for tomorrow? Read on.
StockNews.com ·